Express Pharma

Crohn’s disease treatment market sees major shift with biosimilars and next-gen therapies: GlobalData

The recent launch of adalimumab biosimilars not only will cause an overall reduction in the cost of treatment, but also provide the opportunity for another company to knock AbbVie from its standing as the market leader within CD, says GlobalData Analyst